Next BiomedicalLtd (A389650) Stock Overview
Engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A389650 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Next Biomedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩68,100.00 |
| 52 Week High | ₩86,500.00 |
| 52 Week Low | ₩27,250.00 |
| Beta | 0 |
| 1 Month Change | -2.58% |
| 3 Month Change | 51.67% |
| 1 Year Change | 59.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 187.34% |
Recent News & Updates
Shareholder Returns
| A389650 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -0.1% | -0.6% | 4.5% |
| 1Y | 59.1% | -23.7% | 34.3% |
Return vs Industry: A389650 exceeded the KR Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: A389650 exceeded the KR Market which returned 34.3% over the past year.
Price Volatility
| A389650 volatility | |
|---|---|
| A389650 Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 10.4% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A389650's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A389650's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | n/a | www.nextbiomedical.co.kr |
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization.
Next Biomedical Co.,Ltd. Fundamentals Summary
| A389650 fundamental statistics | |
|---|---|
| Market cap | ₩553.44b |
| Earnings (TTM) | ₩2.57b |
| Revenue (TTM) | ₩12.16b |
Is A389650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A389650 income statement (TTM) | |
|---|---|
| Revenue | ₩12.16b |
| Cost of Revenue | ₩4.29b |
| Gross Profit | ₩7.88b |
| Other Expenses | ₩5.30b |
| Earnings | ₩2.57b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 316.77 |
| Gross Margin | 64.75% |
| Net Profit Margin | 21.16% |
| Debt/Equity Ratio | 25.6% |
How did A389650 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 04:06 |
| End of Day Share Price | 2025/10/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Next Biomedical Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.